Bank of New York Mellon Corp Takes Position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY)

Bank of New York Mellon Corp acquired a new position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) during the first quarter, according to its most recent filing with the SEC. The institutional investor acquired 7,377 shares of the company’s stock, valued at approximately $297,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. First Trust Advisors LP increased its position in Dr. Reddy’s Laboratories by 35.8% in the first quarter. First Trust Advisors LP now owns 166,142 shares of the company’s stock worth $6,671,000 after buying an additional 43,755 shares during the period. Russell Investments Group Ltd. increased its position in Dr. Reddy’s Laboratories by 99.1% in the first quarter. Russell Investments Group Ltd. now owns 54,626 shares of the company’s stock worth $2,194,000 after buying an additional 27,189 shares during the last quarter. US Bancorp DE increased its position in Dr. Reddy’s Laboratories by 12.7% in the first quarter. US Bancorp DE now owns 84,723 shares of the company’s stock worth $3,402,000 after buying an additional 9,538 shares during the last quarter. Pillar Pacific Capital Management LLC increased its position in Dr. Reddy’s Laboratories by 7.6% in the first quarter. Pillar Pacific Capital Management LLC now owns 24,270 shares of the company’s stock worth $975,000 after buying an additional 1,720 shares during the last quarter. Finally, Sumitomo Life Insurance Co. increased its position in Dr. Reddy’s Laboratories by 40.0% in the first quarter. Sumitomo Life Insurance Co. now owns 4,200 shares of the company’s stock worth $169,000 after buying an additional 1,200 shares during the last quarter. Hedge funds and other institutional investors own 15.25% of the company’s stock.

Dr. Reddy’s Laboratories Ltd (NYSE RDY) traded down 0.23% during trading on Friday, reaching $30.75. 171,222 shares of the company’s stock traded hands. Dr. Reddy’s Laboratories Ltd has a 12 month low of $30.22 and a 12 month high of $50.10. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of 28.77 and a beta of 0.33. The firm’s 50 day moving average is $37.81 and its 200-day moving average is $40.55.

The firm also recently declared a None dividend, which was paid on Thursday, August 10th. Investors of record on Monday, July 17th were issued a $0.294 dividend. The ex-dividend date of this dividend was Thursday, July 13th. Dr. Reddy’s Laboratories’s dividend payout ratio is 27.88%.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/7377-shares-in-dr-reddys-laboratories-ltd-nyserdy-acquired-by-bank-of-new-york-mellon-corp-updated.html.

A number of research firms have recently issued reports on RDY. BidaskClub downgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Zacks Investment Research upgraded shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, July 14th. Deutsche Bank AG upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. Finally, CLSA cut shares of Dr. Reddy’s Laboratories from an “underperform” rating to a “sell” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating and two have issued a hold rating to the company’s stock. Dr. Reddy’s Laboratories presently has an average rating of “Hold”.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Institutional Ownership by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

What are top analysts saying about Dr. Reddy's Laboratories Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dr. Reddy's Laboratories Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit